@Article{,
AUTHOR = {Robert Dreicer},
TITLE = {How to approach sequencing therapy  in patients with metastatic castration  resistant prostate cancer},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {21},
YEAR = {2014},
NUMBER = {Suppl.2},
PAGES = {93--97},
URL = {http://www.techscience.com/CJU/v21nSuppl.2/63018},
ISSN = {1488-5581},
ABSTRACT = {<b>instruction:</b> Introduction: Rapid progress has recently been made in understanding the biology of advanced prostate cancer. This has translated into the development of a number of novel agents to treat metastatic castration-resistant prostate cancer (mCRPC).<br/>

<b>instruction:</b> Materials and methods: The relevant literature was retrieved from a search of MEDLINE with appropriate keywords.<br/>

<b>instruction:</b> Results: Therapeutic approaches to mCRPC include chemotherapy, hormonal manipulation, immunotherapy and radioisotope therapy. Docetaxel and cabazitaxel are cytotoxic agents which have demonstrated a modest impact on survival. Hormonal manipulation with abiraterone and enzalutamide have also been reported to be beneficial in mCRPC. The radioisotope radium-223 utilizes a novel approach in treating mCRPC and was recently described in a positive phase III trial. Finally, sipuleucel-T is an immunotherapy that has a demonstrated overall survival benefit in mCRPC.<br/>

<b>instruction:</b> Conclusions: A number of phase III trials have been published that describe agents which are beneficial in treating mCRPC. Future research will focus on sequencing these agents in a clinically rational and economically viable manner.},
DOI = {}
}